Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer

Cell Rep. 2022 Mar 1;38(9):110460. doi: 10.1016/j.celrep.2022.110460.

Abstract

We report a comprehensive proteomic study of a 90-case cohort of paired samples of triple-negative breast cancer (TNBC) in quantification, phosphorylation, and DNA-binding capacity. Four integrative subtypes (iP-1-4) are stratified on the basis of global proteome and phosphoproteome, each of which exhibits distinct molecular and pathway features. Scaffold and co-expression network analyses of three proteomic datasets, integrated with those from genome and transcriptome of the same cohort, reveal key pathways and master regulators that, characteristic of TNBC subtypes, play important regulatory roles within and between scaffold sub-structures and co-expression communities. We find that NAE1 is a potential drug target for subtype iP-1, and a series of key molecules in fatty acid metabolism, such as AKT1/FASN, are plausible targets for subtype iP-2. Libraries of proteins, pathways and networks of TNBC provide a valuable molecular infrastructure for further clinical exploration and in-depth studies of the molecular mechanisms of the disease.

Keywords: TNBC molecular library; drug target; integrated network analysis; integrative multi-omics analysis; proteomic subtyping; triple-negative breast cancer (TNBC).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genome
  • Humans
  • Proteome / genetics
  • Proteomics
  • Transcriptome
  • Triple Negative Breast Neoplasms* / genetics
  • Triple Negative Breast Neoplasms* / metabolism

Substances

  • Proteome